- Home
- AIFF vs CODX Comparison
AIFF vs CODX Comparison
Compare AIFF & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- CODX
- Stock Information
- Founded
- AIFF 2006
- CODX 2013
- Country
- AIFF Canada
- CODX United States
- Employees
- AIFF N/A
- CODX N/A
- Industry
- AIFF
- CODX Medical/Dental Instruments
- Sector
- AIFF
- CODX Health Care
- Exchange
- AIFF NYSE
- CODX Nasdaq
- Market Cap
- AIFF 26.6M
- CODX 22.0M
- IPO Year
- AIFF N/A
- CODX 2017
- Fundamental
- Price
- AIFF $3.78
- CODX $0.32
- Analyst Decision
- AIFF
- CODX Hold
- Analyst Count
- AIFF 0
- CODX 1
- Target Price
- AIFF N/A
- CODX $1.00
- AVG Volume (30 Days)
- AIFF 981.8K
- CODX 265.5K
- Earning Date
- AIFF 05-21-2025
- CODX 03-27-2025
- Dividend Yield
- AIFF N/A
- CODX N/A
- EPS Growth
- AIFF N/A
- CODX N/A
- EPS
- AIFF N/A
- CODX N/A
- Revenue
- AIFF $74,000.00
- CODX $3,915,160.00
- Revenue This Year
- AIFF N/A
- CODX N/A
- Revenue Next Year
- AIFF N/A
- CODX N/A
- P/E Ratio
- AIFF N/A
- CODX N/A
- Revenue Growth
- AIFF N/A
- CODX N/A
- 52 Week Low
- AIFF $1.86
- CODX $0.28
- 52 Week High
- AIFF $17.20
- CODX $2.23
- Technical
- Relative Strength Index (RSI)
- AIFF 44.05
- CODX 22.45
- Support Level
- AIFF $4.47
- CODX $0.28
- Resistance Level
- AIFF $5.87
- CODX $0.50
- Average True Range (ATR)
- AIFF 0.70
- CODX 0.06
- MACD
- AIFF -0.02
- CODX -0.01
- Stochastic Oscillator
- AIFF 24.45
- CODX 11.79
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support better outcomes for people suffering from mental illnesses and cognitive disorders.
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.